DeBere will actively invest and organise investment syndicate with pedigree institutional Venture Capitalists and Corporate Partners. We will add strategic value across the lifecycle of the company, facilitating fundraising to exit.
We are interested in the following Lifescience themes:
Drug development and therapeutics that are groundbreaking in the treatment and cure of cancer
Treatment and cure of Alzheimer's and Parkinson's disease
TargaGenix – ($15m Round B) – Oncology
Developing novel therapeutics addressing unmet medical needs for the treatment of cancer.
Clearlight Diagnostics – ($10m Round C) – Diagnostics
Developing a novel next generation approach to processing and visualizing cancer tissue.